← All trials
NCT06755450
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 15, 2025
- Primary completion
- Jan 15, 2027
- Completion date
- Jan 15, 2028
- First posted
- Jan 1, 2025
- Last posted
- Aug 26, 2025
- Enrollment
- 40
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Aurigene Discovery TechnologiesLead sponsor
- Aurigene Discovery TechnologiesOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.